This narrative review argues that neurodegeneration can be driven by toxic RNA species and RNA-protein dysregulation, emphasizing mechanisms in repeat-expansion (“RNAopathies”) and RNA-binding protein–pathologies (e.g., TDP-43/FUS), with special attention to animal-model evidence.
Target paper: Belzil, Gendron & Petrucelli, “RNA-mediated toxicity in neurodegenerative disease” (Mol. Cell. Neurosci., 2013).
Key organizing idea: multiple RNA-derived mechanisms may coexist and converge on shared downstream cell-stress pathways, so the most testable hypothesis is not “one RNA mechanism explains all,” but rather “which RNA mechanism dominates by disease, cell type, and temporal stage.”
From sequence-level pathology → RNA species → RNA-binding protein disruption → transcription/translation/stress changes → neuronal death (with multiple possible entry points).
This table is a critique map: it distinguishes (i) what the review presents as supported observations, (ii) what it frames as mechanistic inference, and (iii) what it acknowledges as still unresolved.
| Mechanistic claim (review) | Typical evidence cited/used by the review | Confidence (within this review’s framing) | Key uncertainty / skeptical check |
|---|---|---|---|
| RNA foci form from expanded repeat transcripts; RBPs can be sequestered | Human tissue/cell localization; model systems showing foci and RBP colocalization | Moderate (observational consistency across several disorders) | Correlation vs causation for neuronal death; foci vs other toxic species |
| Bidirectional transcription across repeats can yield both sense and antisense products | Transcript mapping in disease loci and models; phenotypes linked to expanded repeats | Moderate | Which product is toxic may differ; may coexist with protein gain-of-function |
| RAN translation produces toxic homopolymeric peptides without canonical AUG start | Model systems demonstrating noncanonical translation from repeat RNAs and disease-relevant expression | Moderate-to-strong (mechanistic plausibility; multiple disease contexts discussed) | How dominant RAN products are in human neurons at specific disease stages remains open |
| Epigenetic changes & haploinsufficiency contribute to disease | Chromatin/methylation observations linked to repeat expansion loci | Moderate | Epigenetic changes may be downstream; disease heterogeneity can blur causality |
| RNA-binding proteinopathies (TDP-43/FUS) involve loss vs gain mechanisms | Protein mislocalization/inclusions, RNA target dysregulation, transgenic rodent phenotypes | Moderate | Many models lack classic cytoplasmic inclusions; toxic species could be soluble mislocalized forms |
| In c9ORF72 ALS/FTD, RNA foci and TDP-43 pathology co-occur | Neuropathology + repeat transcript localization in patient tissue | Moderate for co-occurrence; weak for causal coupling (in this review) | Unresolved whether RNA foci trigger TDP-43 pathology or represent parallel toxic processes |
Poly-mechanism convergence is plausible, but the unifying framework can under-specify which step is the earliest causal bottleneck across diseases.
A helpful way to calibrate the review’s RNA-centric emphasis is to compare it with later reviews focused specifically on RNA-mediated neurodegeneration in repeat expansion disorders.
Tap an author to see BGPT’s author-focused review links.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.